Pivot Bio Elevates Three Leaders and Announces New Environmental Policy Appointment
Appointments Strengthen Growth, People Strategy, Manufacturing and Environmental Leadership
- Ryan Degnan, chief growth officer
Laureen Thompson , chief human resources officerBalaji Venkataraman , chief supply chain officer
Each of these leaders reports to
"These leadership advancements reflect the momentum Pivot Bio is building and our continued commitment to putting farmers first," said
Additionally, the company announced that it has appointed
"Marty brings more than three decades of exceptional leadership to this new role at Pivot Bio," said
The company's advancements and appointments are effective immediately.
About
As the chief growth officer,
Degnan joined Pivot Bio in 2025 as head of growth from McKinsey & Company, where he worked across the firm's chemicals and agriculture, sustainability, and growth marketing and sales practices. While there, he succeeded in launching new ventures and driving growth in a variety of agriculture and agtech-focused businesses spanning inputs, distribution, digital software, hardware and data.
Prior to joining McKinsey, Degnan served in the U.S. Army as a military intelligence officer, holding leadership positions across a variety of strategic and tactical units in
He has an MBA from Yale School of Management and a BBA from the University of Notre Dame's Mendoza College of Business.
About
Thompson joined Pivot Bio in 2022 as senior director of total rewards, and advanced to head of people and human resources for the company in
Her career began at Prudential. During her time there, she was selected to serve in its rotational leadership program. She went on to spend more than a decade at Willis Towers Watson as a consultant and 16 years at VWR/Avantor, where she served as global vice president of total rewards and played a key role in executing two IPOs.
Thompson earned a Bachelor of Arts in education from Arcadia University and an MBA from LaSalle University. She is active in the human resources field and serves on several nonprofit boards.
About
Venkataraman joined Pivot Bio in 2023 to lead the company's in-house and third-party manufacturing, supply chain and procurement functions. He oversees Pivot Bio's relationships with contract manufacturers; the company's
Venkataraman brings decades of expertise as a global operations leader transforming supply chains, working with his teams to deliver operational excellence, and optimizing processes to improve safety and profitability. Before joining Pivot Bio, he served as vice president of global operations at Corteva Agriscience. Prior to that, he held a variety of manufacturing leadership roles across Dow companies, including the agriculture division of DowDuPont and Dow Chemical in the
About
He brings more than two decades of sustainability, policy and regulatory leadership experience from Cargill, most recently as renewable fuels sustainability lead, building low-carbon pathways across agriculture and alternative feedstock supply chains. He has also held senior sustainability, issues management and government relations roles at Cargill and previously served as state government affairs director for Kimberly-Clark.
In his new role, Muenzmaier will help ensure Pivot Bio remains proactive and responsible in how it engages on environmental issues relevant to farmers, partners and the agricultural industry.
About Pivot Bio
Pivot Bio, one of the world's leading innovative agtech companies, delivers to farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs in the face of increasing volatility.
Currently available in
View original content to download multimedia:https://www.prnewswire.com/news-releases/pivot-bio-elevates-three-leaders-and-announces-new-environmental-policy-appointment-302673154.html
SOURCE Pivot Bio
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
- Last Chance to Join the Apeing Whitelist Before This Upcoming Crypto Coin Rivals Monero and Ethereum
- Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical Programs
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share